Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acetazolamide for Drive-Dependent OSA
NCT06091085Phase 2
Key facts
- Status
- Recruiting
- Start
- Jan 2024
- Primary completion
- Dec 2027
- Countries
- 1
- Sponsor
- Brigham and Women's Hospital
- Modality
- Small Molecules
- Drugs
- acetazolamide
- Conditions
- obstructive sleep apnea (OSA)
01
Overview
Phase 2, randomised, double-blind trial in obstructive sleep apnea (OSA) comparing Acetazolamide with Placebo (2 arms). Primary endpoint: Percentage reduction of Apnea-Hypopnea Index. Started Jan 2024; status: recruiting.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Acetazolamide
Acetazolamide 250-500mg
Placebo
Matching placebo
03
Who it enrols
Adults with suspected or diagnosed OSA, untreated or washed out, without unstable medical conditions, heart failure, or other respiratory disorders.
04
Endpoints
Primary
Percentage reduction of Apnea-Hypopnea Index
Secondary
Hypoxic burden
Arousal index
N1 sleep percentage
Beyond the preview
Go deeper on NCT06091085.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06091085.